

FINANCIAL FORECAST

BRIEFING SESSION

**Barry Greene, Tony Dutson
& Aurelia Nguyen**

27 November 2018, Geneva



Decisions for consideration at this Board meeting

Decisions for consideration by the Board	US\$ million	Decision amount	Already in Forecast	Addition to Forecast 2016-2020	Addition to Forecast 2021-2025
(a) Vaccine Investment Strategy - Cholera (Bridge Funding & Learning Agenda) <i>Investment return: Direct Health impact</i>		44	1	43	
(b) Vaccine Investment Strategy - excl Cholera Bridge Funding <i>Investment return: Direct Health impact</i>				VIS	360
(c) Vaccine Investment Strategy - Learning Agenda, excl Cholera <i>Investment return: Direct Health impact</i>		7	3	4	13
(d) Gavi's support for IPV post 2020 <i>Investment return: Global Health Security</i>					850
(e) Pandemic Influenza Preparedness <i>Investment return: Global Health Security</i>		2	1	1	2
(f) India: IPV support (if at upper range of options) <i>Investment return: Global Health Security</i>		40		40	
(g) Gavi Support for Yellow Fever Diagnostic Capacity <i>Investment return: Direct Health impact</i>		8	2	6	5
(h) CEPI -- Fully funded by specific pledge from Kingdom of Norway to IFFIm <i>Investment return: Global Health Security</i>		77		77	
(i) Engagement with Country Post-Transition: Angola and Timor-Leste <i>Investment return: Direct Health impact</i>		2		2	8
(j) Congo Republic exceptional eligibility 2019 (note 4) <i>Investment return: Direct Health impact</i>		4	4		
(k) 2019 UNICEF Procurement Fees - CCEOP		4.3	3.6	0.7	
				174	1,238
				\$0.2 bn	\$1.2 bn

Impact on forecast expenditure

Evolution of expenditure, before new decisions

Expenditure estimate US\$ million cash-flow basis	Last Forecast Nov 2017 Board	Decisions already made this year
2016-2020	9,205 \$9.2 bn	353 \$200m IPV 2019-2020, \$61m Nigeria, \$52m Cholera, etc.
2021-2025 tentative	8,299 \$8.3 bn	422 \$396 Nigeria, \$26m PCV catch up

Evolution of expenditure, before new decisions

Expenditure estimate US\$ million cash-flow basis	Last Forecast Nov 2017 Board	Decisions already made this year	Change upon updating estimates	Sub-total prior to Nov 2018 decisions	
2016-2020	9,205 \$9.2 bn	353	(524)	9,034 \$9.0 bn	Supply constraints – Rota, HPV Price assumptions
2021-2025 tentative	8,299 \$8.3 bn	422	(1,367)	7,354 \$7.4 bn	Critical review of assumptions, including for country readiness

Evolution of expenditure, including new decisions

Expenditure estimate US\$ million cash-flow basis	Last Forecast Nov 2017 Board	Decisions already made this year	Change upon updating estimates	Sub-total prior to Nov 2018 decisions	Impact of Nov 2018 decisions	New Forecast Nov 2018 Board									
2016-2020	9,205 \$9.2 bn	353	(524)	9,034 \$9.0 bn	174	9,207 \$9.2 bn	<table border="1"> <tr><td>VIS</td><td>47</td></tr> <tr><td>CEPI</td><td>77</td></tr> <tr><td>India IPV</td><td>40</td></tr> <tr><td>Other</td><td>10</td></tr> </table>	VIS	47	CEPI	77	India IPV	40	Other	10
VIS	47														
CEPI	77														
India IPV	40														
Other	10														
2021-2025 tentative	8,299 \$8.3 bn	422	(1,367)	7,354 \$7.4 bn	1,238	8,593 \$8.6 bn	<table border="1"> <tr><td>VIS</td><td>373</td></tr> <tr><td>IPV post-2020</td><td>850</td></tr> <tr><td>Other</td><td>15</td></tr> </table>	VIS	373	IPV post-2020	850	Other	15		
VIS	373														
IPV post-2020	850														
Other	15														

Evolution of expenditure, including new decisions

Expenditure estimate US\$ million cash-flow basis	Last Forecast Nov 2017 Board	Decisions already made this year	Change upon updating estimates	Sub-total prior to Nov 2018 decisions	Impact of Nov 2018 decisions	New Forecast Nov 2018 Board
2016-2020	9,205 \$9.2 bn	353	(524)	9,034 \$9.0 bn	174	9,207 \$9.2 bn
2021-2025 tentative	8,299 \$8.3 bn	422	(1,367)	7,354 \$7.4 bn	1,238	8,593 \$8.6 bn

Potentially,
plus \$500m for
strategic investments
and Malaria

Provision, for
consideration in
context of 2021-
2026 strategy

Resourcing of needs, including the new decisions

Expenditure estimate
US\$ million, cash-flow basis

New
Forecast
Nov 2018
Board

Assured
resources

Formulaic
Allowance
for additional
contributions

2016-2020

\$9.2 bn

\$9.4 bn

\$0.4 bn

2021-2025 tentative

\$8.6 bn

\$1.7 bn

\$7.2 bn

This is NOT an
estimate of 2021-
2026 resources

Potentially plus
\$500m for strategic
investments and Malaria

\$9.1 bn

2016-2020

detail of forecast expenditure

Expenditure Forecast 2016 - 2020

US\$ million, cash-flow

2016-2020

	Last Forecast Nov 2017 Board	Decisions already made this year	Change upon updating estimates	Sub-total prior to Nov 2018 decisions
Vaccine programmes - excluding IPV	5,214	118	(462)	4,870
Vaccine programmes - IPV	251	200	5	456
HSIS programmes	1,950	15	(19)	1,946
CCEOP programmes	200			200
CEPI				
PEF - Programmatic	961	20	(32)	949
Programmatic Expenditure	8,576	353	(508)	8,421
Operating Expenditure *	628	0	(16)	613
Total Expenditure	9,205	353	(524)	9,034
	\$9.2 bn	\$0.4 bn	(\$0.5 bn)	\$9.0 bn

Supply constraints on

- Rotavirus
- HPV

Nigeria,
IPV,
Cholera,
etc.

*Secretariat & Partners OpEx

Expenditure Forecast 2016 - 2020

US\$ million, cash-flow

2016-2020

	Last Forecast Nov 2017 Board	Decisions already made this year	Change upon updating estimates	Sub-total prior to Nov 2018 decisions	Impact of Nov 2018 decisions in 2016-2020	New Forecast Nov 2018 Board
Vaccine programmes - excluding IPV				4,870	56	4,926
Vaccine programmes - IPV				456	40	496
HSIS programmes				1,946		1,946
CCEOP programmes				200		200
CEPI					77	77
PEF - Programmatic				949	1	950
Programmatic Expenditure				8,421	174	8,595
Operating Expenditure *				613	0	613
Total Expenditure	9,205	353	(524)	9,034	174	9,207
	\$9.2 bn	\$0.4 bn	(\$0.5 bn)	\$9.0 bn	\$0.2 bn	\$9.2 bn

Overall unchanged since 2017

*Secretariat & Partners OpEx

Nigeria	61
IPV	200
Cholera	52
Pneumo	19
Other	36

VIS	47
CEPI	77
India IPV	40
Other	10

2021-2025

detail of projected expenditure

Expenditure Projection 2021 – 2025 (tentative)

US\$ million, cash-flow basis

2021-2025

	Last Forecast Nov 2017 Board	Decisions already made this year	Change upon updating estimates	Sub-total prior to Nov 2018 decisions
Vaccine programmes, excluding IPV	4,430	347	(755)	4,022
IPV				
HSIS programmes	1,887	75	(436)	1,526
CCEOP programmes	250		(50)	200
PEF - Programmatic	1,076		(126)	950
Programmatic Expenditure	7,643	422	(1,367)	6,698
Operating Expenditure *	657			657
Total Expenditure	8,299	422	(1,367)	7,354
	\$8.3 bn	\$0.4 bn	(\$1.4 bn)	\$7.4 bn

Critical review of estimates yielded **reduction of \$1.4 bn**

- Typhoid
- Measles-Rubella
- Cash-based support
- PEF programmatic

*Secretariat & Partners OpEx

Nigeria, 396
Pneumo 26

Expenditure Projection 2021 – 2025 (tentative)

US\$ million, cash-flow basis

2021-2025

	Last Forecast Nov 2017 Board	Decisions already made this year	Change upon updating estimates	Sub-total prior to Nov 2018 decisions	Impact of Nov 2018 decisions in 2021-2025	New Forecast Nov 2018 Board
Vaccine programmes, excluding IPV				4,022	360	4,382
IPV					850	850
HSIS programmes				1,526		1,526
CCEOP programmes				200		200
PEF - Programmatic				950	28	978
Programmatic Expenditure				6,698	1,238	7,936
Operating Expenditure *				657	0	657
Total Expenditure	8,299	422	(1,367)	7,354	1,238	8,593
	\$8.3 bn	\$0.4 bn	(\$1.4 bn)	\$7.4 bn	\$1.2 bn	\$8.6 bn

VIS & IPV decisions will add \$1.2 bn



Net increase of \$0.3 bn

Nigeria, Pneumo

VIS IPV

*Secretariat & Partners OpEx



Expenditure Projection 2021 – 2025 (tentative)

US\$ million, cash-flow basis

2021-2025

	Last Forecast Nov 2017 Board	Decisions already made this year	Change upon updating estimates	Sub-total prior to Nov 2018 decisions	Impact of Nov 2018 decisions in 2021-2025	New Forecast Nov 2018 Board
Vaccine programmes, excluding IPV						4,382
IPV						850
HSIS programmes						1,526
CCEOP programmes						200
PEF - Programmatic						978
Programmatic Expenditure						7,936
Operating Expenditure *						657
Total Expenditure	8,299	422	(1,367)	7,4	1,238	8,593
	\$8.3 bn	\$0.4 bn	(\$1.4 bn)	\$7.4 bn	\$1.2 bn	\$8.6 bn

For future consideration: **\$500 m provision** (as in Gavi 4.0)

*Secretariat & Partners OpEx

For future consideration in Gavi 5.0 context: Provision for Strategic Investments and Malaria

\$ 0.5 bn


As in 2016-2020

Overview of expenditure

Current portfolio of support

- Existing country approvals *
- Projected country requests

Proposed additions to portfolio



*For simplicity, includes operating expenditure

The majority of expenditure is for the already approved portfolio of vaccines and cash-based support

Recommendation:

The Gavi Alliance Audit and Finance Committee reviewed the Financial Forecast and recommended to the Gavi Alliance Board that it:

- a) **Approve** the Financial Forecast for the period 2016-2020 as set out in Section B of Doc 04.
- b) **Take note of** the indicative Financial Projections for the 2021-2025 period, as set out in Section B of Doc 04, which is based on existing and anticipated programmatic commitments but is dependent on Board approval of the next Gavi Strategy, and any potential programmatic and policy shifts for the given period.
- c) **Authorise** the Gavi Secretariat to allot funding in 2019 for new programmes and for the continuation and adjustment of funding to existing programmes, in accordance with the Programme Funding Policy. In making such allotment decisions, the Secretariat will take into consideration the development of the strategy for the 2021-2025 period.
- d) **Approve** within the overall Partners Engagement Framework: an amount of US\$ 0.7 million in 2019 for UNICEF Supply Division for fees to implement cold chain equipment, in addition to the US\$ 3.6 million already approved for 2019 by the Board in November 2017

Thank you



www.gavi.org